Envestnet Portfolio Solutions Inc. increased its stake in shares of argenx SE (NASDAQ:ARGX – Free Report) by 7.9% in the 4th quarter, Holdings Channel reports. The firm owned 1,509 shares of the ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition that leads to reddening of the skin and the formation of painful and intensely itchy chronic lesions and blisters ...

Farther Finance Advisors LLC grew its stake in shares of argenx SE (NASDAQ:ARGX – Free Report) by 38.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 76 shares ...

The oral mucosa represents a fascinating scenario in the setting of medical research for its peculiar immune mileu. Not only the oral cavity hosts specific immune cells interacting with the local ...

Autoimmune bullous diseases are often associated with significant morbidity and some can even cause mortality, if left untreated. Multiple therapies are now available to treat these blistering ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

From wetting the bed to acne, we have crunched the numbers on the success rate of every single disability claim. It comes ...

AAD 2025 Upadacitinib Dosing Increases or Decreases Found Safe in AD A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

After hours: March 21 at 7:28:33 PM EDT Loading Chart for SNY ...

After hours: 18 March at 7:16:59 pm GMT-4 Loading Chart for SNY ...

After hours: March 21 at 4:22:53 PM EDT Loading Chart for ARGX ...